loading...| Preferred Name |
Asparaginase Erwinia chrysanthemi |
|
| Synonyms |
Recombinant Asparaginase erwinia chrysanthemi JZP-458 RC-P JZP-458 Asparaginase erwinia chrysanthemi-rywn Asparaginase Erwinia chrysanthemi Recombinant Erwinia asparaginase JZP-458 Crisantaspasum Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn Recombinant Crisantaspase JZP-458 Crisantaspase Biobetter JZP-458 Crisantaspase ASPARAGINASE ERWINIA CHRYSANTHEMI Asparaginase Erwinia chrysanthemi-rywn Erwinase Erwinaze JZP 458 JZP-458 JZP458 PF743 Rylaze |
|
| Definitions |
A recombinant form of asparaginase derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration, asparaginase Erwinia chrysanthemi hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase Erwinia chrysanthemi can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C64260 |
|
| Accepted_Therapeutic_Use_For |
Acute lymphocytic leukemia; Acute non-lymphocytic leukemia |
|
| CAS_Registry |
9015-68-3 |
|
| code |
C64260 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
A recombinant form of asparaginase derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration, asparaginase Erwinia chrysanthemi hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase Erwinia chrysanthemi can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products. |
|
| Display_Name |
Asparaginase Erwinia chrysanthemi |
|
| FDA_UNII_Code |
D733ET3F9O |
|
| FULL_SYN |
Recombinant Asparaginase erwinia chrysanthemi JZP-458 RC-P JZP-458 Asparaginase erwinia chrysanthemi-rywn Asparaginase Erwinia chrysanthemi Recombinant Erwinia asparaginase JZP-458 Crisantaspasum Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn Recombinant Crisantaspase JZP-458 Crisantaspase Biobetter JZP-458 Crisantaspase ASPARAGINASE ERWINIA CHRYSANTHEMI Asparaginase Erwinia chrysanthemi-rywn Erwinase Erwinaze JZP 458 JZP-458 JZP458 PF743 Rylaze |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Asparaginase Erwinia chrysanthemi |
|
| Legacy Concept Name |
Asparaginase-Erwinia |
|
| Maps_To |
Asparaginase Erwinia chrysanthemi Recombinant Erwinia asparaginase JZP-458 |
|
| NCI_Drug_Dictionary_ID |
601044 |
|
| NSC Number |
106977 |
|
| PDQ_Closed_Trial_Search_ID |
601044 |
|
| PDQ_Open_Trial_Search_ID |
601044 |
|
| Preferred_Name |
Asparaginase Erwinia chrysanthemi |
|
| prefixIRI |
Thesaurus:C64260 |
|
| Semantic_Type |
Pharmacologic Substance Enzyme |
|
| UMLS_CUI |
C0771210 |
|
| subClassOf |